Shanghai Fosun Pharmaceutical (SHA:600196) obtained registrations for two drugs from China's food and drug administrator, according to a Monday filing with the Shanghai bourse.
Polymyxin B sulfate for injection is intended for treating gram-negative bacterial infections resistant to conventional therapy, while labetalol hydrochloride injection is used to treat severe hypertension and for controlling hypotension during anesthesia.
Shares of the pharmaceutical company were down 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.